Table of Contents
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported) August 15, 2006
BARR PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 1-9860 | 42-1612474 | ||
| (State or other jurisdiction | (Commission | (IRS Employer | ||
| of incorporation) | File Number) | Identification No.) | ||
| 400 Chestnut Ridge Road, Woodcliff Lake, NJ | 07677 | |||
| (Address of principal executive offices) | (Zip code) |
(201) 930-3300
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
| o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
TABLE OF CONTENTS
| Item 2.02 Results of Operations and Financial Condition | ||||||||
| Item 9.01 Financial Statements and Exhibits | ||||||||
| SIGNATURES | ||||||||
| EX-99.1: EARNINGS RELEASE | ||||||||
Table of Contents
Item 2.02 Results of Operations and Financial Condition.
On August 15, 2006, Barr Pharmaceuticals, Inc. (the “Company”) issued a press release
announcing results for the three and twelve months ended June 30, 2006. A copy of the release is
being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by
reference. The information furnished in this Item 2.02 and in Exhibit 99.1 below shall not be
deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor
shall it be deemed incorporated by reference in any filing with the Securities and Exchange
Commission.
The Company will host a Conference Call at 8:30 AM Eastern time on Tuesday, August 15th to
discuss the results. The number to call from within the United States is (800) 230-1059 and (651)
291-5254 Internationally. A replay of the conference call will be available from 12 Noon Eastern
time on August 15th through 11:59 PM Eastern time August 17th, and can be accessed by dialing (800)
475-6701 in the United States or (320) 365-3844 Internationally and using the access code 837996.
The Conference Call will also be Webcast live on the Internet. Investors and other interested
parties may access the live webcast through the Investors section, under Calendar of Events, on
Barr’s website at http://www.barrlabs.com.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits:
| 99.1 | Barr Pharmaceuticals, Inc. August 15, 2006 earnings release. |
Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| BARR PHARMACEUTICALS, INC. | ||||
Date: August 15, 2006
|
/s/ William T. McKee | |||
| William T. McKee | ||||
| Vice President, Chief Financial Officer, and Treasurer | ||||